Abstract
No optimal treatment modality is currently available for the treatment of recurrent epistaxis in HHT. In this review, different therapeutic concepts are discussed together with their pathophysiologic background. Patients often profess a preventive effect for nasal ointments and use packings which can be self-administed in the case of bleeding. An effective first-line treatment for physicians is the endonasal laser coagulation or argon plasma coagulation. A second line surgical procedure is septodermoplasty according to Saunders which can provide long-lasting relief if performed correctly. There have been reports on antifibrinolytic agents and hormones, but their efficacy has yet to be determined.
Keywords: Rendu-Osler-Weber disease, hereditary haemorrhagic telangiectasia, laser therapy, septodermoplasty, review
Current Pharmaceutical Design
Title: Treatment of Recurrent Epistaxis in HHT
Volume: 12 Issue: 10
Author(s): U. W. Geisthoff, M. L. Fiorella and R. Fiorella
Affiliation:
Keywords: Rendu-Osler-Weber disease, hereditary haemorrhagic telangiectasia, laser therapy, septodermoplasty, review
Abstract: No optimal treatment modality is currently available for the treatment of recurrent epistaxis in HHT. In this review, different therapeutic concepts are discussed together with their pathophysiologic background. Patients often profess a preventive effect for nasal ointments and use packings which can be self-administed in the case of bleeding. An effective first-line treatment for physicians is the endonasal laser coagulation or argon plasma coagulation. A second line surgical procedure is septodermoplasty according to Saunders which can provide long-lasting relief if performed correctly. There have been reports on antifibrinolytic agents and hormones, but their efficacy has yet to be determined.
Export Options
About this article
Cite this article as:
Geisthoff W. U., Fiorella L. M. and Fiorella R., Treatment of Recurrent Epistaxis in HHT, Current Pharmaceutical Design 2006; 12 (10) . https://dx.doi.org/10.2174/138161206776361255
DOI https://dx.doi.org/10.2174/138161206776361255 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Food-derived bioactive peptides against chronic diseases
Chronic diseases, such as cardiovascular diseases and metabolic diseases, have become a great threat to the human health in recent decades due to the excessive food consumption and the prevalence of sedentary lifestyle. As a class of natural compounds, food-derived bioactive peptides have been demonstrated to possess great potential for ...read more
Innovative delivery systems and formulations for the management of diseases affecting the skin and skin appendages
Skin and skin appendage diseases have high incidence and can highly impact the quality of life. Such diseases include pigmentation disorders, such as melasma, vitiligo and post-inflammatory hyperpigmentation, infectious diseases caused by fungi, viruses, bacteria and parasites, inflammatory diseases such as acne, dermatitis, rosacea, and psoriasis, as well as skin ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Skin Cancers in Elderly Patients
Anti-Cancer Agents in Medicinal Chemistry Mast Cells as Targets of Pimecrolimus
Current Pharmaceutical Design Editorial [Hot Topic: Targeting Mast Cells and Basophils in Allergy and Beyond: Emerging Concepts (Executive Guest Editor: Petr Heneberg)]
Current Pharmaceutical Design Biomarkers to Assess the Targeting of DNA Repair Pathways to Augment Tumor Response to Therapy
Current Molecular Medicine Ophthalmological and Otological Manifestations in the Antiphospholipid Syndrome
Current Rheumatology Reviews Clinical Value of Prostacyclin and its Analogs in the Management of Pulmonary Arterial Hypertension
Current Vascular Pharmacology Patent Selections:
Recent Patents on CNS Drug Discovery (Discontinued) Molecular Modeling of Sulfonylmorpholinopyrimidines as the Ataxia Telangiectasis Mutated and RAD3-related (ATR) Protein Kinase Inhibitors by Computational Explorations
Letters in Drug Design & Discovery Treatment of Choroidal Neovascularization in High Myopia
Current Drug Targets Micronized Purified Flavonoid Fraction (MPFF)*: A Review of its Pharmacological Effects, Therapeutic Efficacy and Benefits in the Management of Chronic Venous Insufficiency
Current Vascular Pharmacology Systemic Sclerosis: Clinical Manifestations
Current Rheumatology Reviews Arthropathy in Patients with CREST Variant Scleroderma
Current Rheumatology Reviews Update on Etiology and Pathogenesis of Biliary Atresia
Current Pediatric Reviews Medical Treatment of Chronic Venous Insufficiency
Vascular Disease Prevention (Discontinued) Matrix Metalloproteinases as Potential Targets in the Venous Dilation Associated with Varicose Veins
Current Drug Targets